


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/436,892
				Filing Date	11/9/99
				First Named Inventor	Medford
				Group Art Unit	1646
				Examiner Name	
Sheet 1 of 3	Attorney Docket Number ATH111				




U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
JS	AA	4,522,811		Eppstein et al.	06-11-1985	
JS	AB	5,155,250		Parker et al.	10-13-1992	
JS	AC	5,262,439		Parthasarathy	11-16-1993	
JS	AD	5,380,747		Medford et al.	01-10-1995	
JS	AE	5,608,095		Parker et al.	03-04-1997	
JS	AF	5,750,351		Medford et al.	05-12-1998	
JS	AG	5,773,209		Medford et al.	06-30-1998	
JS	AH	5,773,231		Medford et al.	06-30-1998	
JS	AI	5,792,787		Medford et al.	08-11-1998	
JS	AJ	5,807,884		Medford et al.	09-15-1998	
JS	AK	5,811,449		Medford et al.	09-22-1998	
JS	AL	5,846,959		Medford et al.	12-08-1998	
JS	AM	5,877,203		Medford et al.	03-02-1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
JS	AN	WO	WO 95/15760		Merrell Dow Pharma.	06-15-1995		✓
JS	AO	WO	WO 98/51662		AtheroGenics, Inc.	11-19-1998		
JS	AP	WO	WO 98/51289		AtheroGenics, Inc.	11-19-1998		
	AQ	FR	2168137		Dynachim	08-31-1973		
	AR	FR	2140771		Aries	01-19-1973		
	AS	FR	2140769		Aries	01-19-1973		
	AT	FR	2134810		Aries	11-13-1972		
	AU	FR	2133024		Aries	11-24-1972		
	AV	FR	2130975		Aries	11-10-1972		

Examiner Signature	<i>Dorlene B. Grubel</i>	Date Considered	1/24/01
--------------------	--------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				C m p l t e i f K n w n	
				Applicati n Number	09/436,892
				Filing Dat	11/9/99
				First Named Inventor	Medford
				Group Art Unit	1646
Examiner Name					
Sheet	2	of	3	Attorney Docket Number	ATH111



OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
<i>SS</i>	CA	BROWN, L., and Langer, R., Transdermal Delivery of Drugs, Annual Review of Medicine, 39:221-229 (1988),	
<i>SS</i>	CB	BROWN, M.S. and Goldstein, J. L Sci. American (1984) 251, 58-66.	
<i>SS</i>	CC	CAREW et al. Proc. Natl. Acad. Sci. U.S.A. 84:7725-7729 (1987)	
<i>SS</i>	CD	ENDO A:	
<i>SS</i>	CE	GALEANO, N. F. et al., J. Biol. Chem. vo. 269, no. 1, pp. 511-519, 1994.	
<i>SS</i>	CF	GOLDSTEIN, J.L. and Brown, M.S.: Ann. Rev. Biochem. (1977) 46, 897-930.	
<i>SS</i>	CG	GRUNDY S.M. New Engl. J. Med. (1988) 319: 24-32	
<i>SS</i>	CH	GRUNDY S.M., Vega G.L.: Amer J. Med. (1987) 83:9-20.	
<i>SS</i>	CI	INNERARITY, T., et al., Proc. Natl. Acad. Sci. USA, vol. 84, pp. 6919-23, 1987.	
<i>SS</i>	CJ	YANG et al. Nature (1986) 323:734-738.	
<i>SS</i>	CK	MILNE, R. et al., J. Biol. Chem. vol. 264, no. 33, 1988, pp. 10754-60.	
<i>SS</i>	CL	MILNE, R. et al., Arteriosclerosis, vol. 3, no. 1, 1983, pp. 23-30.	
<i>SS</i>	CM	SIRTORI, C.R., Franceschini G.: Pharmac Ther. (1988) 37:167-191.	
<i>SS</i>	CN	STEDRONSKY ER: Biochim. Biophys. Acta(1994) 1210:255-287.	
<i>SS</i>	CO	WANG X, Bucala R, Milne R. Proc. Natl. Acad. Sci (1998) 95:7643-7647.	
<i>SS</i>	CP	WEISGRABER, K. H., et al., J. Biol. Chem., vol. 258, No. 20, October 25, 1983, pp. 12348-12354.	
<i>SS</i>	CQ	WILSON M.D., Rudel L.L.: J. Lipid Res. (1994) 35:943-955.	
<i>SS</i>	CR	YOUNG, et al. J. Clin. Invest., Vol. 79, June 1987, 1831-1841.	
<i>SS</i>	CS	W. FRISHMAN, M.DZIMETBAUM, P., M.D., and H. Eder, M.D.: Clin. Pharmacol. (1990) 30:3-9.	

Examiner Signature	<i>Anilene A. Patel</i>	Date Considered	<i>1/24/01</i>
--------------------	-------------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form hould be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.

+

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MAY 08 2000

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	09/436,892
--------------------	------------

Filing Date	11/9/99
--------------------	---------

First Named Inventor	Medford
----------------------	---------

Group Art Unit	1646
----------------	------

Examiner Name

Attorney Docket Number | ATH111

[illegible][illegible]

Examiner
Signature

Arileene R. Dabel

Date 1/24/01
Considered

1/24/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.**

+

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

Complete if Known

Application Number	09/436,892
--------------------	------------

Filing Date	11/9/99
--------------------	---------

First Named Inventor	Medford
----------------------	---------

Group Art Unit	1646
----------------	------

Examiner Name

Attorney Docket Number	ATH111
------------------------	--------

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner
Initials*Cite
No.

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

—

BA

BB

KNOTT, TJ, et al. Complete protein sequence and identification of structural domains of human apolipoprotein B," *Nature*, 232, 734-738, 1986.

apolipoprotein B," *Nature*, 232, 734-736, 1980.

YANG, C.Y. et al. Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100 *Nature* 323, 738-742 (1986).

**Examiner
Signature**

Donlene B. Zabel

Date
Considered

1/24/61

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.**

PTO/SR/08A (10-96)

Please type a plus sign (+) inside this box

+

PTO/SB/08A (10-96)